drugset / Trial / NCT00015951
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
Phase 2
Completed
University of Maryland, Baltimore
National Cancer Institute (NCI) · collabUniversity of Maryland Greenebaum Cancer Center · collab
Treatment
Summary
RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine and mitoxantrone in treating patients who have hematologic cancer.
Timeline
- Start
- 2001-04
- Primary completion
- 2003-04
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Cytarabine | Small molecule | — | Intravenous |
| Subject | Mitoxantrone | Small molecule | — | Intravenous |